scholarly journals Chronic Idiopathic Constipation in Adults: A Review on Current Guidelines and Emerging Treatment Options

2021 ◽  
Vol Volume 14 ◽  
pp. 413-428
Author(s):  
Gabrio Bassotti ◽  
Paolo Usai Satta ◽  
Massimo Bellini
Keyword(s):  
Treatment Options ◽  
Idiopathic Constipation ◽  
Chronic Idiopathic Constipation ◽  
Current Guidelines

scholarly journals Plecanatide: a new guanylate cyclase agonist for the treatment of chronic idiopathic constipation

2018 ◽  
Vol 11 ◽  
pp. 175628481877794 ◽  
Author(s):  
Satish S.C. Rao
Keyword(s):  
Guanylate Cyclase ◽  
Treatment Options ◽  
Structural Analog ◽  
Drug Dose ◽  
Double Blind ◽  
Idiopathic Constipation ◽  
Spontaneous Bowel Movement ◽  
Chronic Idiopathic Constipation ◽  
Rome Iii ◽  
The Usa

Chronic constipation affects millions of Americans, consumes significant healthcare resources, and significantly affects quality of life (QOL). Recently, several new treatment options have become available for the treatment of constipation, including intestinal secretagogues such as lubiprotone, and linaclotide, prokinetics such as prucalopride, and bile acid transporter antagonists. Plecanatide is the newest of the secretagogue class of compounds that has been approved by the US Food and Drug Administration for the treatment of adults with chronic idiopathic constipation (CIC) in the USA. It is a guanylate cyclase agonist, and a 16 amino acid synthetic peptide that is a structural analog of human uroguanylin. Two large randomized, double-blind, placebo-controlled studies assessed the efficacy and safety of plecanatide in CIC patients (Rome III). Both doses of plecanatide, 3 mg and 6 mg resulted in a significantly greater percentage of patients who were durable overall complete spontaneous bowel movement (CSBM) responders (primary endpoint) compared with those who received placebo (plecanatide 3 mg, 21.0%; plecanatide 6 mg, 19.5%; placebo, 10.2%; p < 0.001 for each drug dose versus placebo). Plecanatide treatment also significantly reduced the severity of other CIC symptoms (straining effort, stool consistency, bloating). Also, plecanatide-treated patients reported high levels of satisfaction and improved QOL and desire to continue treatment. The rate of treatment-emergent adverse events with plecanatide was low, including rates of diarrhea (5%). Plecanatide is a luminally acting secretagogue that is efficacious and safe for the treatment of CIC. This article provides an overview of plecanatide in the management of adults with CIC.

scholarly journals Review of Treatment Options for Irritable Bowel Syndrome with Constipation and Chronic Idiopathic Constipation

2021 ◽  
Vol Volume 14 ◽  
pp. 1457-1468
Author(s):  
Sarah Patel ◽  
Bethany Doerfler ◽  
Katerine Boutros ◽  
Samson Ng ◽  
Machelle Manuel ◽  
...  
Keyword(s):  
Irritable Bowel Syndrome ◽  
Treatment Options ◽  
Idiopathic Constipation ◽  
Chronic Idiopathic Constipation ◽  
Irritable Bowel

scholarly journals Defining a responder in treatment trials for chronic idiopathic constipation: authors’ reply

2010 ◽  
Vol 33 (2) ◽  
pp. 286-287
Author(s):  
A. W. Mangel ◽  
J. F. Johanson ◽  
Y.-P. Li ◽  
K. Kersey ◽  
O. Daniels
Keyword(s):  
Idiopathic Constipation ◽  
Chronic Idiopathic Constipation ◽  
Treatment Trials
Sign in / Sign up

Export Citation Format

Share Document